anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Schistosoma japonicum infection causes hepatic fibrosis, a primary cause of morbidity and mortality associated with the disease, and effective treatments are still lacking. Long non-coding RNAs (lncRNAs) have been implicated in the pathogenic process of various tissue fibroses. However, the role of lncRNAs in schistosomiasis hepatic fibrosis (HF) is poorly understood. Understanding the role of lncRNAs in schistosomiasis HF will enhance knowledge of disease processes and aid in the discovery of therapeutic targets and diagnostic biomarkers.
METHODS: Differentially expressed lncRNA profiles in primary hepatic stellate cells (HSCs) of mice infected with S. japonicum were identified using high-throughput lncRNA sequencing. Primary HSCs were isolated from infected mice using collagenase digestion and density-gradient centrifugation, cultured in DMEM with 10% fetal bovine serum. Dual-luciferase reporter assays, nuclear cytoplasm fractionation and RIP assays were employed to assess the relationship between Malat1 and miRNA-96. Malat1 lentivirus and ASO-Malat1 were constructed for forced expression and downregulated expression of Malat1. The Malat1-KO mouse was constructed by CRISPR/Cas9 technology. Pathological features of the liver were evaluated by hematoxylin-eosin (HE), Masson's trichrome staining and immunohistochemistry (IHC). The expression levels of fibrosis-related genes were determined by quantitative real-time PCR (qRT-PCR) and Western blot.
RESULTS: A total of 1561 differentially expressed lncRNAs were identified between infected and uninfected primary HSCs. Among the top altered lncRNAs, the downregulated Malat1 was observed in infected HSCs and verified by qPCR. Treatment of infected mice with praziquantel (PZQ) significantly increased the Malat1 expression. Elevated Malat1 expression in infected primary HSC reduced the expressions of profibrogenic genes, whereas Malat1 knockdown had the opposite effect. Moreover, Malat1 was found to interact with miR-96, a profibrotic miRNA, by targeting Smad7. Forced Malat1 expression reduced miR-96 levels in infected primary HSCs, attenuating fibrogenesis and showing negative correlation between Malat1 expression and the expression levels of miR-96 and profibrogenic genes α-SMA and Col1α1. Notably, in Malat1-KO mice, knockout of Malat1 aggravates schistosomiasis HF, while restored Malat1 expression in the infected HSCs reduced the expression of profibrogenic genes.
CONCLUSIONS: We demonstrate that lncRNA is involved in regulation of schistosomiasis HF. Elevated lncRNA Malat1 expression in infected HSCs reduces fibrosis via the Malat1/miR-96/Smad7 pathway, thus providing a novel therapeutic target for schistosomiasis HF. Furthermore, Malat1 expression is sensitive to PZQ treatment, thus offering a potential biomarker for assessing the response to chemotherapy.
Participants will be randomized to one of two cohorts: (1) the intervention cohort will participate in an online team-based game on diabetes self-management education (DSME) and will receive a paper documents on American history, and (2) the 'attention control' cohort will participate in an online team-based game on American history and will receive a paper documents on DSME. Each game would consist of 2 questions per week x 25 weeks = 50 questions total per arm. The questions are delivered via email by the Qstream platform to the participants. Upon clicking on a hyperlink in the email, participants select an answer that is downloaded to a server. They are then provided with the answer to and explanation of the question, along with additional educational materials. Using an adaptive methodology, the spacing and content of the game material will be individualized for each clinician based on their performance. Home-based testing of HbA1c and M/C ratio will be conducted by patients at enrollment, 6 months and 12 months. If successful, this SE game will improve diabetes management among VA patients and improve patient outcomes. Given the growing use of email and the Internet by patients, SE games could be easily expanded to a broad audience of VA patients with varying health problems across the country. With content tailored to meet specific needs, SE games can be utilized as tools to improve patients' clinical outcomes by bolstering their health management behaviors.
Solution of NaHA 20 mg/1.1 ml pre-filled syringe for intraocular use. Animal derived 1.8% sodium hyaluronate OVD.
Research of disease-related factors, research of comorbidities, geriatric assessment (Mini Mental Status Examination (MMSE), Geriatric Depression Scale-15, Mini Nutritional Assessment, Short Physical Performance Battery, grip strength, Fried criteria, Activities of Daily Living (ADL), Instrumental-ADL, G8, self-reported health status, quality of life Quality of Life Questionnaire-C30, Elderly Cancer Patients-14, EQ5D) at inclusion. At 3 months ADL and physical performance. Grade 3/4 toxicities and serious adverse events will be assessed during 6 months after inclusion (using NCI-COMMON TERMINOLOGY CRITERIA version 2.0) whatever treatment type (chemotherapy, supportive care).
Liver diseases have a global prevalence of 25%, accounting for 4% of all deaths worldwide, and are associated with a 36% increased risk of fatal and nonfatal cardiovascular events. Metabolic dysfunction-associated steatotic liver disease constitutes the liver expression of metabolic syndrome and represents the primary type of liver disease. Microscopical analysis of biopsies, which allows the evaluation of a small portion of tissue with inferences made to the entire organ, is considered the gold standard for determining the presence of liver diseases. However, potential sampling errors in liver biopsies are conceivable because the obtained tissue represents only a tiny fraction of the entire liver mass and may not accurately reflect the true pathological state. Studies have demonstrated the existence of sampling errors in liver biopsies, particularly concerning the severity of inflammation, degree of fibrosis, and the presence of cirrhosis. Also, clinical studies have shown that histopathological abnormalities are better detected in humans when liver samples are collected from both the right and the left lobes. However, a gap exists in clinical investigation to clarify the role of differences between these lobes in improving the diagnostic and prognostic for liver diseases. Building upon the heterogeneous nature of pathological alterations observed in liver lobes, this perspective review provided recommendations to enhance the precision of diagnosis and prognostic accuracy of liver diseases.
NEW MATERIAL:A compound shown by the formula (R is pyridinecarbonyl) and its pharmaceutically acceptable salt. EXAMPLE:2-Palmitoylaminoethyl isonicotinate. USE:A drug having antiphlogistic and immune-enhancing action. Since it increases fat solubility and promotes absorption from the intestine, a given effect can be obtained by its small amount, has a little side effects such as gastroenteric disorder, etc. and strengthens pharmaceutical action. PROCESS:For example, 2-palmitoylamino ethanol is reacted with a carboxylic acid anhydride or a carboxylic acid halide or a palmitic acid halide is reacted with a carboxylic acid 2-aminoethyl ester, to give an amide ester compound shown by the formula.
The invention provides a preparation method of a traditional Chinese medicine for treating hunger type frostbite, belonging to the technical field of a preparation method of traditional Chinese medicines. At present, sulfonamides and antibiotics are generally used for treating hunger type frostbite. Kanamycin has toxicity to the acoustic nerve and kidney. The preparation method provided by the invention comprises the following steps of: taking and putting bighead atractylodes rhizome, milk vetch, caryophyllaceous ginseng, jujube, sealwort, bidens tripartita, cotton root, prepared rehmannia root, angelica, white peony root, rhizoma cyperi, costus root, radix linderae, green tangerine peel, radix asteris, toosendan fruit, citron bark, fingered citron, agilawood, rose, citron, monkshood, asarum, pepper, long pepper extract, cubeb, fennel, chives, galangal, common cnidium fruit, chili, caraway, rhizoma kaempferiae, szechuan aconite, acontum fischeri, clematis root and licorice into water for soaking; then, decocting with soft fire; and filtering for removing dregs to obtain a liquid medicine, namely the traditional Chinese medicine for treating hunger type frostbite. The liquid traditional Chinese medicine prepared by the preparation method provided by the invention has the advantages of small toxic side effect, short course of treatment and high cure rate. Monarch, minister, assistant and guide drugs are synergetic.
Patients visiting one of the study clinics during the Maintenance period of the CHIMES intervention. Data will be abstracted from medical records of visits that occur during study Months 28 - 33.
An eight-week Internet-based self-guided treatment, delivered with guidance on demand from therapists in training. The treatment is based on cognitive behavior therapy and includes both cognitive interventions, e.g., cognitive restructuring and behavioral experiments, and behavioral interventions, behavioral activation. The treatment was manualized by Egan et al. (2016) and has been tested in several clinical trials, both via the Internet and face-to-face.
The present disclosure provides uses of phosphodiesterase 5 (PDE-5) and/or phosphodiesterase 6 (PDE-6) inhibitor compounds and uses of compositions including said compounds. In some embodiments, said compounds are nitrogen oxide (NO) donating PDE-5 and/or -6 inhibitor compounds that include a nitrogen oxide-containing donor substituent attached to a benzenesulfonamide group. The compounds can provide dual functionality for increasing protein kinase G (PKG) activity by inhibiting PDE-5 and PDE-6, and/or stimulating guanylate cyclase via donation of NO from the donor substituent of the compound. The present disclosure also provides methods of using said compounds and compositions for inhibiting PDE-5 and/or -6 and increasing activity of PKG. The compounds and compositions find use in the treatment of a variety of eye diseases. For example, the subject compounds may be used as a therapeutic agent for glaucoma, age-related macular degeneration, diabetic retinopathy, xerophthalmia, dry eye syndrome, cataracts or uveitis.
The present invention provides for novel sustained release silk-based delivery systems. The invention further provides methods for producing such formulations. In general, a silk fibroin solution is combined with a therapeutic agent to form a silk fibroin article. The article is then treated in such a way as to alter its conformation. The change in conformation increases its crystallinity or liquid crystallinity, thus controlling the release of a therapeutic agent from the formulation. This can be accomplished as single material carriers or in a layer-by-layer fashion to load different therapeutic agents or different concentrations of these agents in each layer.
Participants with diagnosis of acute lower extremity DVT (proximal and distal) and/or pulmonary embolism will be identified and approached for participation, when they are seen in the Thrombophilia Clinic or Mayo Hospital for management of the acute VTE. If they match the preset inclusion and exclusion criteria, they would then be consented during this visit and scheduled for baseline studies at a later date. Baseline tests include Venous plethysmorgraphy, Lower Extremity Ultrasound, and Medical history, will be conducted and if eligible, participant will then be randomized to vascular boot plus standard anti coagulation program or standard anti coagulation using a randomization program. Participants will be randomized into two groups and followed for 3 months. Standard of Care (SOC) Group (no vascular boot utilized): Patients will receive standard anticoagulation (determined at discretion of the treating provider), baseline studies, and follow up at the end of treatment (3months). Vascular Boot (VB) Group (includes vascular boot in addition to SOC): Patients will receive standard anticoagulation (determined at discretion of the treating provider), baseline studies and standardized vascular boot warming. All patients randomized to this group will wear the vascular boot for a minimum of 30 minutes per day for the first 10 days of participation. Patients in this group may initially be enrolled at either the thrombophilia clinic or the hospital.
PURPOSE: A handheld ultrasound system is provided to supply an even operating method to a user by supplying a user interface in an area in which a user request has been inputted. CONSTITUTION: A mobile ultrasound system comprises an ultrasonic probe. A main body(110) forms an ultrasonic image of an object. The main body offers a user interface which is operable by a hand gripping the main body. A touch screen(120) is arranged on one side of the main body. The touch screen displays the ultrasonic image and the user interface. The touch screen receives user setting information from the user.
Cardiac surgery patients are at risk for perioperative bleeding and transfusion due to the invasiveness of the surgery and an acquired coagulopathy that is unique to this sub-specialty. High transfusion rates in this population are related to surgical field blood loss and the development of a multi-factorial coagulopathy. Due to these circumstances, cardiac surgery patients account for up to 20% of total annual blood transfusion with a subset of high risk patients consuming 80% of all transfusion in this group. On this basis, employing blood conservation methods is extremely relevant as the use of donated blood products leads to greater rates of infectious complications, atrial fibrillation, prolonged postoperative ventilation, acute renal injury, and reduced short and long-term survival in cardiac surgery patients. Reducing the health and cost burden associated with transfusion is an important outcome to both the patient and health care system. Intraoperative autologous whole blood transfusion, a blood-conservation method similar to acute normovolemic hemodilution, may reduce transfusion and its associated complications but there is a paucity of large scale prospective randomized control trials investigating its efficacy in the era of modern surgical approaches, targeted transfusion using point-of-care viscoelastic testing, and advanced perfusion techniques. The intent of this study is to assess the feasibility of a trial protocol for a large-scale national study investigating high volume autologous whole blood transfusion for reduction in allogenic transfusion, derivative administration, and transfusion-associated morbidity and mortality.
PROBLEM TO BE SOLVED: To produce a composition, comprising ascorbic acids and barbaloin and capable of preserving the barbaloin in a state of an aqueous solution for a long period. SOLUTION: This composition comprises one or more of compounds (ascorbic acids) selected from L-ascorbic acid and an alkali metallic salt, a fatty acid ester, phosphoric ester or a saccharide transfer product (e.g. a glucose transfer product) thereof and barbaloin. A juice or an extract solution obtained from a leaf part in an aloe of a plant belonging to the genus Aloe of the family Liliaceae containing the barbaloin or other terrestrial parts by pressing of the juice, leaching, extraction, etc., and a concentrate, a purified substance, etc., are used as the barbaloin. The extraction is carried out by using a hydrous ethanol at normal temperatures or under refluxing and heating. The barbaloin is stabilized by blending with the ascorbic acids, but more stabilized by the coexistence of the ethanol therewith.  Laxative actions of the barbaloin in the form of a readily ingestible substance, beverage, etc., can be utilized.
Atomoxetine increased the risk of suicidal ideation in short-term studies in children or adolescents with Attention-Deficit/Hyperactivity Disorder (ADHD). Anyone considering the use of atomoxetine in a child or adolescent must balance this risk with the clinical need. Co-morbidities occurring with ADHD may be associated with an increase in the risk of suicidal ideation and/or behavior. Patients who are started on therapy should be monitored closely for suicidality (suicidal thinking and behavior), clinical worsening, or unusual changes in behavior. Families and caregivers should be advised of the need for close observation and communication with the prescriber. Atomoxetine is approved for ADHD in pediatric and adult patients.

Atomoxetine is not approved for major depressive disorder.

Pooled analyses of short-term (6 to 18 weeks) placebo-controlled trials of atomoxetine in children and adolescents (a total of 12 trials involving over 2200 patients, including 11 trials in ADHD and 1 trial in enuresis) have revealed a greater risk of suicidal ideation early during treatment in those receiving atomoxetine compared to placebo. The average risk of suicidal ideation in patients receiving atomoxetine was 0.4% (5/1357 patients), compared to none in placebo-treated patients (851 patients). No suicides occurred in these trials [see Warnings and Precautions (5.1)].
A substantially dry solid vitamin preparation is obtained by suspending particles of a solid water-soluble acid vitamin and particles of a dry alkaline substance in an oil-soluble vitamin-bearing liquid, emulsifying the resulting suspension in a warm aqueous solution containing gelatin to form an emulsion in which the aqueous solution constitutes the continuous phase and the gelatin is of a concentration which will gel upon cooling, the quantity of the alkaline substance being such as to produce in the final emulsion of pH of 3.5-4.8, sub-dividing the emulsion into units of the desired shape, causing the units to gel and drying the product.  The acid vitamin may be ascorbic acid, nicotinic acid or pantothenic acid alone or in admixture with theamine hydrochloride, riboflavin, pyridoxine and/or nicotinic acid amide. The oil-soluble-vitamin-bearing liquid may be vitamin A, vitamin D, or both or oils such as fish liver oils, containing these vitamins, alpha-tocopheral (vitamin E) may also be introduced into the oil phase.  The alkaline substance may be sodium potassium, calcium or magnesium hydroxide.  The solid water-soluble acid vitamin and solid alkaline substance may be suspended in separate portions of the oil-soluble vitamin or oil containing it, these separate portions being emulsified in succession in the gelatine solution to form a polyphase emulsion.  A further quantity of the oil sufficient to produce the desired proportion thereof in the final product may be emulsified in the polyphase emulsion.  The aqueous gelatine solution may contain a plasticizer such as honey, or corn syrup.  The warm emulsion may be formed into the desired shapes which are gelled by cooling.  Specifications 489,970, 490,001 and 541,663 are referred to.
NEW MATERIAL:A benzothiazine derivative shown by the formula I (R<1> is lower alkyl; X<1> and X<2> are halogen) and its salt. EXAMPLE:7,8-Dichloro-2,3-dihydro-3-methyl-4H-benzothiazine. USE:An intermediate for synthesizing a pyrido[1,2,3-de][1,4]benzothiazine derivative useful as a remedy for diseases caused by various kinds of pathogenic microorganisms of men, animals, fishes, etc., surgical germicide for medical tools, and disinfectant. Showing improved antibacterial activity against Gram- positive and Gram-negative bacteria, having low toxicity and weak side effect. PROCESS:A compound shown by the formula II (X<3> is halogen) is nitrated to give a compound shown by the formula III, which is reacted with an alkali metal sulfide so that it is dimerized to give a compound shown by the formula IV. This compound is then reduced with iron, etc. to give a compound shown by the formula V, which is reacted with a compound shown by the formula VI (X=X<3>) in the presence of a dehydrohalogenating agent, further reduced with NaBH4, etc. to give a compound shown by the formula I .
Data on the fold increase in peripheral blood CD34+ cell count (cells/mcL) by apheresis day were evaluated in two placebo-controlled clinical studies in patients with NHL and MM (Study 1 and Study 2, respectively). The fold increase in CD34+ cell count (cells/mcL) over the 24-hour period starting from the day prior to the first apheresis and ending the next morning just before the first apheresis is summarized in Table 3. During this 24-hour period, a single dose of plerixafor or placebo was administered 10 to 11 hours prior to apheresis.

### 

In pharmacodynamic studies of plerixafor in healthy volunteers, peak mobilization of CD34+ cells was observed between 6 and 9 hours after administration. In pharmacodynamic studies of plerixafor in conjunction with filgrastim in healthy volunteers, a sustained elevation in the peripheral blood CD34+ count was observed from 4 to 18 hours after plerixafor administration with a peak CD34+ count between 10 and 14 hours.

QT/QTc Prolongation

There is no indication of a QT/QTc prolonging effect of plerixafor in single doses up to 0.40 mg/kg. In a randomized, double-blind, crossover study, 48 healthy subjects were administered a single subcutaneous dose of plerixafor (0.24 mg/kg and 0.40 mg/kg) and placebo. Peak concentrations for 0.40 mg/kg plerixafor were approximately 1.8-fold higher than the peak concentrations following the 0.24 mg/kg single subcutaneous dose.
It is an object of certain embodiments of the present invention to provide compounds useful as analgesics, anti-anflammatories, diuretics, anesthetics and neuroprotective agents, anti-hypertensives, anti-anxioltics; agents for appetite control; hearing regulators; anti-tussives, anti-asthmatics, modulators of locomotor activity, modulators of learning and memory, regulators of neurotransmitter and hormone release, kidney function modulators, anti-depressants, agents to treat memory loss due to Alzheimer's disease or other dementias, anti-epileptics, anti-convulsants, agents to treat withdrawal from alcohol and drugs of addiction, agents to control water balance, agents to control sodium excretion and agents to control arterial blood pressure disorders and methods for administering said compounds. <??>The compounds of the present invention are useful for modulating a pharmacodynamic response from one or more opioid receptors (ORL-1,  mu ,  delta  and  kappa ) centrally and/or peripherally. The response can be attributed to the compound stimulating (agonist) or inhibiting (antagonist) the one or more receptors. Certain compounds can stimulate one receptor (e.g., a  mu  agonist) and inhibit a different receptor (e.g., an ORL-1 antagonist). <??>The present invention in certain embodiments comprises compounds having the general formula (III): <CHEM> wherein  D is a 5-8 membered cycloalkyl, 5-8 membered heterocyclic or a 6 membered aromatic or heteroaromatic group; the other substituents are defined in the claims.